Press Release


Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel
Jan 19, 2023 09:35 JST
Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Israel Ltd., a pharmaceutical sales subsidiary recently established in Tel Aviv in the State of Israel (Israel).
More info..

Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company
Jan 19, 2023 08:07 JST
Eisai Co., Ltd. announced that it has been listed in the 2023 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc.
More info..

Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023
Jan 18, 2023 12:28 JST
Eisai Co., Ltd. announced today the presentation of research across various types of gastrointestinal cancers during the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI23), which is taking place in-person in San Francisco, California and virtually from January 19-21.
More info..

Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan
Jan 16, 2023 17:56 JST
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a marketing authorization application for lecanemab.
More info..

Eisai Launches Renewed Sustainability Page
Jan 13, 2023 14:06 JST
Eisai Co., Ltd. announced that it has renewed the Sustainability page of its corporate website and it is now accessible to the public.
More info..

Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe
Jan 11, 2023 11:52 JST
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a marketing authorization application (MAA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) to the European Medicines Agency (EMA).
More info..

Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Jan 09, 2023 20:55 JST
Eisai Co., Ltd. and Biogen Inc. announced Eisai has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) supporting the conversion of the Accelerated Approval of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use to a traditional approval.
More info..

FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
Jan 09, 2023 19:40 JST
Eisai Co., Ltd. and Biogen Inc. announced today that under the Accelerated Approval Pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb (Brand Name in the U.S.: LEQEMBI) 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ("protofibril")* and insoluble forms of amyloid beta (Abata) for the treatment of Alzheimer's disease (AD).
More info..

Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
Dec 22, 2022 17:07 JST
Astellas Pharma Inc., Eisai Co., Ltd., Daiichi Sankyo Company, Limited and Takeda Pharmaceutical Company Limited. today announced that the four companies have agreed the collaboration to reduce environmental burden in the field of pharmaceutical packaging.
More info..

Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals
Dec 20, 2022 11:01 JST
Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the United States (U.S.) commercial rights for the anti-epileptic drug (AED) Fycompa (generic name: perampanel) CIII to Catalyst Pharmaceuticals, Inc., as well as to provide Catalyst Pharmaceuticals with an exclusive negotiation period for an asset in Eisai's epilepsy pipeline.
More info..

Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases
Dec 15, 2022 11:20 JST
Eisai Co., Ltd. announced today that Eisai and Washington University School of Medicine in St. Louis have entered into a comprehensive research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's disease (PD).
More info..

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
Dec 01, 2022 19:09 JST
Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN, "eribulin") will be presented during the 2022 San Antonio Breast Cancer Symposium (SABCS), which is taking place virtually and in-person in San Antonio, Texas from December 6-10.
More info..

Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
Nov 30, 2022 09:21 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab.
More info..

Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine
Nov 30, 2022 08:31 JST
The rapid publication of the Clarity AD study results demonstrates Eisai's strong commitment to trust and transparency based on Eisai's human health care mission.
More info..

Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies
Nov 29, 2022 18:28 JST
Eisai Co., Ltd. announced that its application for a partial change to label for Aricept (donepezil hydrochloride), a treatment for Alzheimer's disease and dementia with Lewy bodies (DLB) that was discovered and developed in-house, regarding dosage and administration for the treatment of DLB in Japan, has been approved today.
More info..

Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting
Nov 24, 2022 08:04 JST
Eisai Co., Ltd. announced today that the company will have a total of 34 poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel at the 76th American Epilepsy Society Annual Meeting (AES 2022), to be held in Nashville, Tennessee and virtually from December 2-6, 2022.
More info..

To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
Nov 22, 2022 13:10 JST
Shimadzu Corporation (Shimadzu), Eisai Co., Ltd. (Eisai), Oita University, and Usuki City Medical Association hereby announce the commencement of a cohort study using Usuki City as a demonstration site.
More info..

Eisai to Present Full Findings from Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) and Other Alzheimer's Disease Research at The 15th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Nov 21, 2022 10:50 JST
Eisai's AD pipeline, including the company's investigational anti-microtubule binding region (MTBR) tau antibody (E2814), will be presented in four oral and ten poster presentations.
More info..

Metoject Subcutaneous Injection Syringe (Methotrexate) Launched In Japan For Rheumatoid Arthritis
Nov 16, 2022 10:46 JST
Eisai Co., Ltd. and nippon medac Co., Ltd. announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") in Japan.
More info..

Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH
Nov 07, 2022 08:15 JST
Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for muscle relaxant Myonal (generic name: eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon in Asia (9 countries/regions*) to a subsidiary of DKSH Holding Ltd
More info..

Eisai's Sales Subsidiary Collaborates with Thai Life Insurance to Support Access to Treatments for Dementia, Including Alzheimer's Disease, in Thailand
Nov 04, 2022 14:42 JST
Eisai Co., Ltd. announced today that its Thai sales subsidiary Eisai (Thailand) Marketing Co. Ltd. ("Eisai Thailand") made an agreement to collaborate in supporting access to treatments for dementia, including Alzheimer's disease, in Thailand with Thai Life Insurance Public Company Limited, a leading life insurance company in Thailand.
More info..

Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon
Nov 02, 2022 17:34 JST
Eisai Co., Ltd. announced today that it has received notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) that the "all-case study" specified post-marketing observational study condition.
More info..

Eisai Announces Plans to Submit Application for Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies Based on Results of Drug Reexamination
Nov 02, 2022 09:43 JST
Eisai Co., Ltd. announced today that it has received notification that Aricept (donepezil hydrochloride), a treatment for Alzheimer's disease and dementia with Lewy bodies that was discovered and developed in-house, has been granted Category 2* status based on the results of a reexamination of its efficacy, dosage and administration for the treatment of dementia with Lewy bodies (DLB) in Japan.
More info..

Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
Oct 04, 2022 15:44 JST
Eisai Co., Ltd. announced that, as part of the strategic investment towards the realization of its medium-term business plan "EWAY Future & Beyond", it has completed construction of the new injection/research building "Eisai Medicine Innovation Technology Solutions" ("EMITS") at the Kawashima Industrial Park located in Gifu Prefecture, Japan.
More info..

Eisai's Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint
Sep 28, 2022 14:15 JST
Eisai Co., Ltd. and Biogen Inc. announced positive topline results from Eisai's large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab.
More info..

Eisai: Metoject Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis
Sep 26, 2022 19:14 JST
Eisai Co., Ltd. and nippon medac Co., Ltd. today that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare for the indication of the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") for the treatment of rheumatoid arthritis.
More info..

Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Sep 12, 2022 14:37 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) today announced the first presentation of results from the final analysis of the Phase 3 LEAP-002 trial investigating LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA.
More info..

Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022
Sep 12, 2022 08:00 JST
Eisai Co., Ltd. announced today results from a post hoc analysis of three randomized, pivotal, Phase 3 studies.
More info..

Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022
Sep 06, 2022 09:42 JST
Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place virtually and in-person in Paris, France from September 9 to 13.
More info..

Latest Release


More Latest Release >>